
Cervarix

Version GDSv27/IPIv21

Cervarix

Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted)

Qualitative and Quantitative Composition

Suspension for injection.

1 dose (0.5 ml) contains:

Human Papillomavirus type 16 L1 protein ¹	20 micrograms
Human Papillomavirus type 18 L1 protein ¹	20 micrograms
3-O-desacyl-4'-monophosphoryl lipid A (MPL) ²	50 micrograms
Aluminium hydroxide, hydrated ²	0.5 milligrams Al3+
1 L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system	
2 The GlaxoSmithKline proprietary AS04 adjuvant system is composed of aluminium hydroxide and 3-O-desacyl-4'-monophosphoryl lipid A (MPL) (see Pharmacodynamics)	

Clinical Informations

Indications

CERVARIX is indicated from the age of 9 years for the prevention of persistent infection, premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical, vulvar, vaginal and anal cancers (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic Human Papillomaviruses (HPV) (see Warnings and Precautions and Pharmacodynamics).

Dosage and Administration

The vaccination schedule depends on the age of the subject.

Age at the Time of the First Injection

Immunization and schedule

9 to and Including 14 Years

Two doses each of 0.5 ml. The second dose given between 5 and 13 months after the first dose*

or

Three doses each of 0.5 ml at 0, 1, 6 months**

From 15 Years and Above

Three doses each of 0.5 ml at 0, 1, 6 months**

*If the second vaccine dose is administered before the 5th month after the first dose, a third dose should always be administered.

**If flexibility in the vaccination schedule is necessary, the second dose can be administered between 1 month and 2.5 months after the first dose and the third dose between 5 and 12 months after the first dose.

Although the necessity for a booster dose has not been established, an anamnestic response has been observed after the administration of a challenge dose (see Pharmacodynamics).

CERVARIX is for intramuscular injection in the deltoid region (see Warnings and Precautions and Interactions).

Contraindications

CERVARIX should not be administered to subjects with known hypersensitivity to any component of the vaccine (see Qualitative and Quantitative Composition and List of Excipients).

Warnings and Precautions

It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.

As with other vaccines, the administration of **CERVARIX** should be postponed in subjects suffering from acute severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

CERVARIX should under no circumstances be administered intravascularly or intradermally. No data are available on subcutaneous administration of **CERVARIX**.

As for other vaccines administered intramuscularly, **CERVARIX** should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.

As with any vaccine, a protective immune response may not be elicited in all vaccinees.

CERVARIX is a prophylactic vaccine. It is not intended to prevent progression of HPV-related lesions present at the time of vaccination. **CERVARIX** does not provide protection against all oncogenic HPV types (see Pharmacodynamics). Vaccination is primary prevention and is not a substitute for regular cervical screening (secondary prevention) or for precautions against exposure to HPV and sexually transmitted diseases.

Except for asymptomatic human immunodeficiency virus (HIV) infected subjects for whom data are available (see Pharmacodynamics), there are no data on the use of **CERVARIX** in subjects with impaired immune responsiveness such as patients receiving immunosuppressive treatment. For these individuals an adequate immune response may not be elicited.

Duration of protection has not fully been established. Sustained protective efficacy has been observed for up to 9.4 years after the first dose. Long-term studies are ongoing to establish the duration of protection (see Pharmacodynamics).

Interactions

Use with Other Vaccines

CERVARIX can be given concomitantly with any of the following vaccines: reduced antigen diphtheria-tetanus-acellular pertussis vaccine (dTpa), inactivated poliovirus vaccine (IPV) and the combined dTpa-IPV vaccine; meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MenACWY-TT); hepatitis A (inactivated) vaccine (HepA), hepatitis B (rDNA) vaccine (HepB) and the combined HepA-HepB vaccine.

Administration of **CERVARIX** at the same time as Twinrix (combined HepA-HepB vaccine) has shown no clinically relevant interference in the antibody response to the HPV and hepatitis A antigens. Anti-HBs geometric mean antibody titres were lower on co-administration, but the clinical significance of this observation is not known since the seroprotection rates remain unaffected. The proportion of subjects reaching anti-HBs \geq 10mIU/ml was 98.3% for concomitant vaccination and 100% for Twinrix alone.

If **CERVARIX** is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.

Use with Hormonal Contraceptive

In clinical efficacy studies, approximately 60% of women who received **CERVARIX** used hormonal contraceptives. There is no evidence that the use of hormonal contraceptives has an impact on the efficacy of **CERVARIX**.

Use with Systemic Immunosuppressive Medications

As with other vaccines it may be expected that in patients receiving immunosuppressive treatment an adequate response may not be elicited.

Pregnancy and Lactation

Pregnancy

The effect of **CERVARIX** on embryo-foetal, peri-natal and post-natal survival and development has been assessed in rats. Such animal studies do not indicate direct or indirect harmful effects with respect to fertility, pregnancy, embryonal/foetal development, parturition or post-natal development.

Data in pregnant women collected as part of clinical trials, pregnancy registries, and epidemiological studies do not suggest that vaccination with **CERVARIX** alters the risk of abnormal outcomes in neonates including birth defects. Data are insufficient to conclude whether or not vaccination with **CERVARIX** affects the risk of spontaneous abortion.

Women who are pregnant or trying to become pregnant, are advised to postpone vaccination until completion of pregnancy.

Lactation

The effect on breast-fed infants of the administration of **CERVARIX** to their mothers has not been evaluated in clinical studies.

CERVARIX should only be used during breast-feeding when the possible advantages outweigh the possible risks.

Serological data suggest a transfer of anti-HPV16 and anti-HPV18 antibodies via the milk during the lactation period in rats. However, it is unknown whether vaccine-induced antibodies are excreted in human breast milk.

Effects on Ability to Drive and Use Machines

No studies on the effects on the ability to drive or use machines have been performed.

Adverse Reactions

Clinical Trial Data

In clinical studies, a total of approximately 45000 doses of **CERVARIX** were administered to approximately 16000 female subjects aged 9-72 years and approximately 7800 doses were administered to approximately 2600 male subjects aged 10-18 years. These subjects were followed to assess the safety of the vaccine.

The most common reaction observed after vaccine administration was injection site pain which occurred after 78% of all doses. The majority of these reactions were of mild to moderate severity and were not long lasting.

Adverse reactions considered as being at least possibly related to vaccination have been categorized by frequency.

Frequencies are reported as:

Very common	(\geq 1/10)
Common	(\geq 1/100 to <1/10)
Uncommon	(\geq 1/1000 to <1/100)
Rare	(\geq 1/10000 to <1/1000)

Infections and Infestations

Uncommon upper respiratory tract infection

Blood and Lymphatic System Disorders

Uncommon lymphadenopathy

Nervous System Disorders

Very common headache
Uncommon dizziness

Gastrointestinal Disorders

Common gastrointestinal including nausea, vomiting, diarrhoea and abdominal pain

Skin and Subcutaneous Tissue Disorders

Common itching/pruritus, rash, urticaria

Musculoskeletal and Connective Tissue Disorders

Very common myalgia
Common arthralgia

General Disorders and Administration Site Conditions

Very common injection site reactions including pain, redness, swelling, fatigue
Common: Fever (\geq 38°C)
Uncommon other injection site reactions such as induration, local paraesthesia

Post Marketing Data

Immune System Disorders

Rare allergic reactions (including anaphylactic and anaphylactoid reactions), angioedema

Nervous System Disorders

Rare syncope or vasovagal responses to injection, sometimes accompanied by tonic-clonic movements.

Overdose

Insufficient data are available

Pharmacological Properties

Pharmacodynamics

Pharmaco-therapeutic group: Papillomavirus vaccines, J07BM02

Mechanism of Action

Persistent infection with oncogenic HPV types has been demonstrated to be responsible for virtually all cases of cervical cancer worldwide.

CERVARIX is a non-infectious recombinant vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of oncogenic HPV types 16 and 18. Since the VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. Animal studies have shown that the efficacy of L1 VLP vaccines is largely mediated by the development of a humoral immune response and cell-mediated immune memory.

CERVARIX is adjuvanted with AS04 which has been shown in clinical trials to induce a higher and long lasting immune response compared to the same antigens adjuvanted with aluminium salt [Al(OH)₃] alone.

Invasive cervical cancer includes squamous cervical carcinoma (84%) and adenocarcinoma (16%, up to 20% in developed countries with screening programs).

HPV-16 and HPV-18 are responsible for approximately 70% of cervical cancers, 80% of vulvar and vaginal cancers, 90% of anal cancers, 70% of HPV related high-grade anal (VIN 2/3) and vaginal intraepithelial neoplasia (VaIN 2/3) and 78% of HPV related high-grade anal (AIN 2/3) intraepithelial neoplasia across all regions worldwide.

Other oncogenic HPV types (HPV-31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68) can also cause ano-genital cancers. HPV-16, -18, -45 and -31 are the 4 most common types identified in squamous cervical carcinoma (approximately 76%) and adenocarcinoma (approximately 91%).

Evidence of Anamnestic (Immune Memory) Response

The administration of a challenge dose after a mean of 6.8 years following the first vaccination elicited an anamnestic immune response to HPV-16 and HPV-18 (by ELISA and pseudovirion-based neutralizing assay) at day 7. One month after the challenge dose, GMTs exceeded those observed one month after the primary vaccination course.

An anamnestic response was also observed for the related types HPV-31 and HPV-45 by ELISA.

Prophylactic Efficacy

Clinical Efficacy in Women Aged 15 to 25 Years

The efficacy of **CERVARIX** was assessed in 2 controlled, double-blind, randomised clinical studies (HPV-001/007 and HPV-008) that included a total of 19778 women aged 15 to 25 years at enrolment.

Clinical trial HPV-001/007 was conducted in North America and Latin America. Study HPV-023 followed-up subjects from the Brazilian cohort of study 001/007. Study entry criteria were: negative for oncogenic HPV DNA (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68) in cervical samples, seronegative for HPV-16 and HPV-18 antibodies and normal cytology. These characteristics are representative of a population presumed naive to oncogenic HPV types prior to vaccination.

Clinical trial HPV-008 was conducted in North America, Latin America, Europe, Asia Pacific and Australia. Pre-vaccination samples were collected for oncogenic HPV DNA (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68) testing and serum testing for HPV-16 and HPV-18 antibodies. Women were vaccinated regardless of baseline cytology and HPV serological and DNA status. These characteristics are representative of a population which includes women with evidence of past and/or current HPV infection.

As in any prophylactic efficacy trial, subjects initially infected with a particular HPV type were not eligible for the efficacy assessment of that type.

Cervical intraepithelial neoplasia (CIN) grade 2 and 3 (CIN2+) was used in the clinical trials as a surrogate marker for cervical cancer. Persistent infection that lasts for at least 6 months has also been shown to be a relevant surrogate marker for cervical cancer. Although CIN grade 1 is not a surrogate marker for cervical cancer, these lesions require medical follow-up.

1.- Vaccine Efficacy Against HPV-16/18 in Women Naïve to Oncogenic HPV Types (Studies HPV-001/007/023)

Efficacy results for histological endpoints associated with HPV-16 and/or HPV-18 (HPV-16/18) observed in study HPV-001/007 (Total Cohort i.e. women who received at least one vaccine dose) are presented in Table 1.

Table 1: Vaccine efficacy against CIN2+ and CIN1+ associated with HPV-16/18

HPV-16/18 endpoint	CERVARIX N = 481	Control (Aluminium salt) N = 470	% Efficacy (95% CI)
	Number of cases		
CIN2+ ⁽¹⁾	0	9	100% (51.3;100)
CIN1+ ⁽²⁾	0	15	100% (73.4;100)

(1) cervical intraepithelial neoplasia grade 2 and higher grade lesions
(2) cervical intraepithelial neoplasia grade 1 and higher grade lesions

Efficacy against HPV-16/18 cytological abnormalities was 96.7% (95% CI: 87.3;99.6).

Efficacy against HPV-16/18 persistent infection was 98.2% (95% CI: 89.5;100) and 96.9% (95% CI: 81.4;99.9) when using a 6-month and a 12-month definition, respectively.

In study HPV-023, subjects (N=437) were followed-up to 9.4 years (approximately 113 months) after dose one. There were no new cases of infection or histopathological lesions associated with HPV-16/18 in the vaccine group. In the placebo group, there were 4 cases of 6-month persistent infection, 1 case of 12-month persistent infection and 1 case of CIN1+ associated with HPV-16/18.

In the descriptive combined analysis of studies HPV-001/007/023, efficacy against HPV-16/18 incident and 6-month persistent infection was 91.0% (95% CI: 80.3;96.5) and 96.8% (95% CI: 80.4;99.9), respectively. Despite evidence of

continuous exposure to HPV infections as observed in the control group, there is no evidence of waning protection in vaccinated women.

2.- Vaccine Efficacy in Women with Evidence of Past and/or Current HPV Infection (Study HPV-008)

2.1.- Prophylactic Efficacy Against HPV-16/18 in Women Naïve to HPV-16 and/or HPV-18

In study HPV-008, the primary analyses of efficacy were performed on the According to Protocol cohort (ATP cohort: including women who received 3 vaccine doses and were naïve to the relevant HPV type at month 0 and month 6) and the Total Vaccinated Cohort-1 (TVC-1 cohort: including women who received at least one vaccine dose and were naïve to the relevant HPV type at month 0). Both cohorts included women with normal or low-grade cytology at baseline and excluded only women with high-grade cytology (0.5%).

In addition, analyses of efficacy were performed on the broader Total Vaccinated Cohort (TVC) and TVC-naïve.

In study HPV-008, approximately 26% of women had evidence of current and/or prior

HPV-16/18 infection and less than 1% of women were HPV DNA positive for both HPV-16 and HPV-18 types at baseline.

The final analysis of study HPV-008 was event-triggered, i.e. was performed when at least 36 CIN2+ cases associated with HPV-16/18 were accrued in the ATP cohort. The mean follow-up was approximately 39 months post dose one.

End of study analysis was performed at the end of the 4-year follow-up period (i.e. 48 months post dose one) and included all subjects from the Total Vaccinated Cohort (TVC).

In the protocol-specified analysis, vaccine efficacy against CIN1+ and CIN2+ associated with HPV-16/18 was statistically significant in the ATP and TVC-1 cohorts.

Further investigation identified that several CIN3+, CIN1+ and CIN2+ cases had multiple oncogenic HPV types in the lesion. In order to distinguish between the HPV type(s) most likely to be responsible for a lesion, from the HPV type(s) only temporally associated, an HPV type assignment was applied (exploratory analysis). The HPV type assignment considered the HPV types detected by Polymerase Chain Reaction (PCR) in at least one of the two preceding cytologic samples, in addition to types detected in the lesion. Based on this HPV type assignment, the analysis excluded cases (in the vaccine group and in the control group) which were not considered to be causally associated with HPV-16 or HPV-18 infections acquired during the trial.

The results observed in both analysis (i.e. protocol-specified analysis and HPV type assignment) are presented in Table 2.

Table 2: Vaccine efficacy against CIN1+, CIN2+ and CIN3+ associated with HPV-16/18

HPV 16/18 endpoint		Final study analysis				End of study analysis					
		CERVARIX		Control		CERVARIX		Control		% Efficacy (95% CI)	
		N	n	N	n	N	n	N	n		
Protocol-specified analysis (ATP and TVC-1)											
CIN3+	ATP ⁽¹⁾	7344	2	7312	10	80.0% (0.3;98.1)	7338	2	7305	24	91.7% (66.6;99.1)
	TVC-1 ⁽²⁾	8040	2	8080	22	90.9% (60.8;99.1)	8068	2	8103	40	95.0% (80.7;99.4)
CIN2+	ATP ⁽¹⁾	7344	4	7312	56	92.9% (79.9;98.3)	7338	5	7305	97	94.9% (87.7;98.4)
	TVC-1 ⁽²⁾	8040	5	8080	91	94.5% (86.2;98.4)	8068	6	8103	135	95.6% (90.1;98.4)
CIN1+	ATP ⁽¹⁾	7344	8	7312	96	91.7% (82.4;96.7)	7338	12	7305	165	92.8% (87.1;96.4)
	TVC-1 ⁽²⁾	8040	11	8080	135	91.8% (84.5;96.2)	8068	15	8103	210	92.9% (88.0;96.1)
HPV type assignment (exploratory analysis) (ATP and TVC-1)											
CIN3+	ATP ⁽¹⁾	7344	0	7312	8	100% (36.4;100)	7338	0	7305	22	100% (81.8;100)
	TVC-1 ⁽²⁾	8040	0	8080	20	100% (78.1;100)	8068	0	8103	38	100% (89.8;100)
CIN2+	ATP ⁽¹⁾	7344	1	7312	53	98.1% (88.4;100)	7338	1	7305	92	98.9% (93.8;100)
	TVC-1 ⁽²⁾	8040	2	8080	87	97.7% (91.0;99.8)	8068	2	8103	128	98.4% (94.3;99.8)
CIN1+	ATP ⁽¹⁾	7344	2	7312	90	97.8% (91.4;99.8)	7338	3	7305	154	98.1% (94.3;99.6)
	TVC-1 ⁽²⁾	8040	5	8080	128	96.1% (90.3;98.8)	8068	6	8103	196	97.0% (93.3;98.9)

N = number of subjects included in each group
n = number of cases
⁽¹⁾ 3 doses of vaccine, DNA negative and seronegative at month 0 and DNA negative at month 6 to the relevant HPV type (HPV-16 or HPV-18)
⁽²⁾ at least one dose of vaccine, DNA negative and seronegative at month 0 to the relevant HPV type (HPV-16 or HPV-18)

In addition, at the time of final study analysis, statistically significant vaccine efficacy against CIN2+ associated with HPV-16 and HPV-18 individually was demonstrated in both cohorts for each analysis.

Vaccine efficacy against 6-month and 12-month persistent infection and cytological abnormalities (≥ASCUS) associated with HPV-16/18 was also assessed. The observed vaccine efficacy against each endpoint was statistically significant in both cohorts:

At the time of final study analysis:

- 6-month persistent infection: 94.3% (91.5;96.3) in ATP cohort and 90.2% (87.3;92.6) in TVC-1 cohort,
- 12-month persistent infection: 91.4% (86.1;95.0) in ATP cohort and 85.3% (79.9; 89.4) in TVC-1 cohort,
- cytological abnormalities (≥ASCUS): 89.0% (84.9;92.1) in ATP cohort and 86.7% (82.8; 89.8) in TVC-1 cohort.

At the end of study analysis:

- 6-month persistent infection: 94.3% (92.0;96.1) in ATP cohort and 91.0% (88.5;93.0) in TVC-1 cohort,
- 12-month persistent infection: 92.9% (89.4;95.4) in ATP cohort and 88.2% (84.5%; 91.2%) in TVC-1 cohort,
- cytological abnormalities (≥ASCUS): 90.7% (87.8;93.1) in ATP cohort and 88.6% (85.6; 91.0) in TVC-1 cohort.

At the time of the final study analysis, statistically significant vaccine efficacy against VIN1+ (vulvar intraepithelial neoplasia grade 1 and higher grade lesions) or VaIN1+ (vaginal intraepithelial neoplasia grade 1 and higher grade lesions) associated with HPV-16/18 was also observed in both cohorts: 80.0% (96.1% CI: 0.3;98.1) in ATP cohort and 83.2% (96.1% CI: 20.2;98.4) in TVC-1 cohort. At the end of study analysis, vaccine efficacy against VIN1+ or VaIN1+ associated with HPV-16/18 was 75.1% (95% CI: 22.9;94.0) in ATP cohort and 77.7% (95% CI: 32.4;94.5) in TVC-1 cohort. There were 2 cases of VIN2+ or VaIN2+ associated with HPV-16 or HPV-18 in the vaccine group and 7 cases in the control group in the ATP cohort. The study was not powered to demonstrate a difference between the vaccine and the control group for these endpoints.

There was no evidence of protection from disease caused by the HPV types for which subjects were HPV DNA positive at study entry. However, individuals already infected with one of the vaccine-related HPV types prior to vaccination were protected from clinical disease caused by the other vaccine HPV type.

2.2.- Overall Impact of the Vaccine on HPV Disease Burden

The overall vaccine efficacy irrespective of HPV DNA type in the lesion and stratified by baseline HPV DNA and serostatus was evaluated in study HPV-008.

In the TVC and TVC-naïve cohorts which included all vaccinated women, vaccine efficacy against CIN3+, CIN2+ and CIN1+ was demonstrated (Table 3). The impact of **CERVARIX** on reduction of local cervical therapy (Loop Electro-Excision Procedure, Cone, Knife or Laser) was also demonstrated in the same cohorts (Table 3).

The TVC-naïve is a subset of the TVC that includes women with normal cytology, and who were HPV DNA negative for 14 oncogenic HPV types (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68) and seronegative for HPV-16 and HPV-18 at baseline.

Table 3: Vaccine efficacy irrespective of HPV DNA type in the lesion, regardless of initial serostatus

		Final study analysis						End of study analysis					
		CERVARIX		Control		% Efficacy (96.1% CI)	CERVARIX		Control		% Efficacy (95% CI)		
		N	n	N	n		N	n	N	n			
CIN3+	TVC naïve (1)	5449	3	5436	23	87.0% (54.9;97.7)	5466	3	5452	44	93.2% (78.9;98.7)		
	TVC (2)	8667	77	8682	116	33.4% (9.1;51.5)	8694	86	8708	158	45.6% (28.8;58.7)		
CIN2+	TVC naïve (1)	5449	33	5436	110	70.2% (54.7;80.9)	5466	61	5452	172	64.9% (52.7;74.2)		
	TVC (2)	8667	224	8682	322	30.4% (16.4;42.3)	8694	287	8708	428	33.1% (22.2;42.6)		
CIN1+	TVC naïve (1)	5449	106	5436	211	50.1% (35.9;61.4)	5466	174	5452	346	50.3% (40.2;58.8)		
	TVC (2)	8667	451	8682	577	21.7% (10.7;31.4)	8694	579	8708	798	27.7% (19.5;35.2)		
Local cervical therapy	TVC naïve (1)	5449	26	5436	83	68.8% (50.0;81.2)	5466	43	5452	143	70.2% (57.8;79.3)		
	TVC (2)	8667	180	8682	240	24.7% (7.4;38.9)	8694	230	8708	344	33.2% (20.8;43.7)		

N = number of subjects included in each group
n = number of cases
⁽¹⁾ TVC-naïve: includes all vaccinated subjects (who received at least one dose of vaccine) who had normal cytology, were HPV DNA negative for 14 oncogenic HPV types and seronegative for HPV-16 and HPV-18 at baseline.
⁽²⁾ TVC: includes all vaccinated subjects (who received at least one dose of vaccine).

2.3.- Prophylactic Efficacy Against Infection by Oncogenic HPV Types Other Than Hpv-16 And HPV-18

In study HPV-008, vaccine efficacy against 12 non-vaccine oncogenic HPV types (HPV-31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68) was evaluated in ATP and TVC-1 cohorts.

At the time of the final study analysis, statistically significant vaccine efficacy against CIN2+ for all HPV types combined (HPV-31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68) excluding HPV types 16 and 18 was demonstrated with 54.0% (96.1% CI: 34.0;68.4) in ATP cohort and 46.0% (96.1% CI: 27.0;60.3) in TVC-1 cohort. At the end of study analysis, vaccine efficacy against CIN2+ for all HPV types combined excluding HPV types 16 and 18 was 46.8% (95% CI: 30.7;59.4) in the ATP cohort and 40.8% (95% CI: 25.5;53.1) in the TVC-1 cohort.

At the time of the final study analysis, statistically significant vaccine efficacy against 6-month persistent infection and against CIN2+ has been observed for the following individual HPV types:

- 6-month persistent infection: types 31, 33, 45 in ATP cohort; types 31, 33, 45, 51 in TVC-1 cohort.
- CIN2+: types 31, 51, 58 in ATP cohort; types 31, 33, 35, 51 in TVC-1 cohort.

At the end of study analysis, more cases were accrued and a lower limit of the 95% CI above zero has been observed for HPV types 31, 33, 45 and 51 for both 6-month persistent infection and CIN2+ in the ATP and TVC-1 cohorts. For CIN2+, a lower limit of the 95% CI above zero has also been observed for HPV type 39 in the ATP cohort and HPV type 66 in the TVC-1 cohort.

Clinical Efficacy in Women Aged 26 Years and Older

The efficacy of **CERVARIX** was assessed in a double-blind, randomised Phase III clinical trial (HPV-015) that included a total of 5778 women aged 26-72 years (median: 37.0 years). The study was conducted in North America, Latin America, Asia Pacific and Europe. Final analysis was performed at study conclusion, 7 years after the first **CERVARIX** dose.

The primary endpoint was a combination of a virological and a histopathological endpoint: HPV-16/18 related 6-month persistent infection and/or CIN1+. The primary analyses of efficacy were performed on the ATP cohort for efficacy and the TVC which included a subset of up to 15% of women with a history of HPV-associated infection or disease.

Vaccine efficacy at study conclusion is summarized in the following table.

Table 4 - Vaccine efficacy at study conclusion in study HPV-015

Endpoint	ATP ⁽¹⁾			TVC ⁽²⁾		
	CERVARIX	Control	% Efficacy (96.2% CI)	CERVARIX	Control	% Efficacy (96.2% CI)
	n/N	n/N		n/N	n/N	
HPV-16/18						
6M PI and/or CIN1+	7/1852	71/1818	90.5% (78.6; 96.5)	93/2768	209/2778	56.8% (43.8; 67.0)
6M PI	6/1815	67/1786	91.4% (79.4; 97.1)	74/2762	180/2775	60.0% (46.4; 70.4)
ASC-US+	3/1852	47/1818	93.8% (79.9; 98.9)	38/2727	114/2732	67.3% (51.4; 78.5)
Cross protective efficacy						
HPV-31 6M PI	10/2073	29/2090	65.8% (24.9; 85.8)	51/2762	71/2775	29.0% (<0; 52.5)
HPV-45 6M PI	9/2106	30/2088	70.7% (34.2; 88.4)	22/2762	60/2775	63.9% (38.6; 79.6)
HPV-31 ASC-US+	5/2117	23/2127	78.4% (39.1; 94.1)	34/2727	55/2732	38.7% (2.0; 62.3)
HPV-45 ASC-US+	5/2150	23/2125	78.7% (40.1; 94.1)	13/2727	38/2732	66.1% (32.7; 84.1)

N = number of subjects in each group
n = number of subjects reporting at least one event in each group
6M PI = 6-month persistent infection
CI = Confidence Interval
ASC-US = Atypical Cells of Undetermined Significance (abnormal cytology)
⁽¹⁾ ≥ 3 doses of vaccine, DNA negative and seronegative at month 0 (unless specified) and DNA negative at month 6 for the relevant HPV type (HPV-16 and/or HPV-18)
⁽²⁾ at least one dose of vaccine, irrespective of HPV DNA and serostatus (unless specified) at month 0. Includes 15% of subjects with previous history of HPV disease/infection

Clinical Efficacy Against Anal Prevalent Infection in Women Aged 18-25 Years

Study HPV-009 evaluated vaccine efficacy against anal prevalent infection at the 4-year study visit. Vaccine efficacy against HPV-16/18 and against non-vaccine types HPV-31/33/45 is presented in Table 5. Cervical infection in the same women at the same visit was assessed for comparison purpose.

Table 5: Efficacy against anal and cervical prevalent infection associated with HPV-16/18 and HPV-31/33/45 in study HPV-009

		Number of women	Number of HPV-16/18 infections	HPV 16/18 vaccine efficacy (95% CI)	Number of women		Number of HPV-31/33/45 infection	HPV-31/33/45 vaccine efficacy (95% CI)
					HPV group	Control group		
Full cohort*	Anus							
	HPV group	2103	47	62.0% (47.1; 73.1)	HPV group	2103	55	49.4% (30.3; 63.6)
	Control group	2107	124		Control group	2107	109	
	Cervix							
Restricted cohort**	Anus							
	HPV group	1003	8	83.6% (66.7; 92.8)	HPV group	1629	31	61.8% (42.8; 75.0)
	Control group	986	48		Control group	1684	84	
	Cervix							
Full cohort*	Anus							
	HPV group	2103	40	76.4% (67.0; 83.5)	HPV group	2103	76	45.2% (27.7; 58.7)
	Control group	2107	170		Control group	2107	139	
	Cervix							
Restricted cohort**	Anus							
	HPV group	1003	10	87.9% (77.4; 94.0)	HPV group	1629	49	51.3% (31.9; 65.5)
	Control group	986	81		Control group	1684	104	
	Cervix							

HPV group: treatment group vaccinated with **CERVARIX** vaccine
Control group: treatment group vaccinated with modified Havrix vaccine (Hepatitis A vaccine)
*Full cohort included all women with anal specimens available
**Restricted cohort for efficacy against HPV16/18 infection included subjects from the full cohort with no evidence of prevalent cervical HPV 16 and HPV 18 infection or HPV 16 and HPV 18 antibodies before vaccination, who received three doses of the HPV or control vaccines. Restricted cohort for efficacy against HPV-31/33/45 infection included women from the full cohort with no evidence of prevalent cervical HPV 31, 33, or 45 infections before vaccination, and who received three doses of the HPV or control vaccine.

Vaccine-Induced Immunogenicity

The antibody response to HPV-16 and HPV-18 was measured using a type specific ELISA which was shown to strongly correlate with neutralization assays (including pseudovirion-based neutralizing assay developed by the US National Cancer Institute). Transduction of antibodies from serum to the cervical mucosa has been demonstrated in clinical trials.

The immunogenicity induced by three doses of **CERVARIX** has been evaluated in over 5000 female subjects from 9 to 55 years of age and over 800 male subjects aged 10 to 18 years.

In clinical trials, more than 99% of initially seronegative subjects had seroconverted to both HPV type 16 and 18 one month after the third dose. Vaccine-induced IgG Geometric Mean Titres (GMT) were well above titres observed in women previously infected but who cleared HPV infection (natural infection). Initially seropositive and seronegative subjects reached similar titres after vaccination.

Immunogenicity in Women Aged 15 to 25 Years

In study HPV-001/007, the immune response against HPV-16 and HPV-18 was evaluated up to 76 months post dose one in women 15 to 25 years old at the time of vaccination. In study HPV-023, this immune response continued to be evaluated up to 9.4 years post dose one in a subset of the population from study HPV-001/007.

In study HPV-023, 100% of women were seropositive for both HPV-16 and HPV-18 by ELISA or by pseudovirion-based neutralizing assay (PBNA) up to 9.4 years after first vaccination.

Vaccine-induced IgG Geometric Mean Titres (GMT) for both HPV-16 and HPV-18 peaked at month 7 and then declined to reach a plateau from month 18 with no substantial decline up to the end of the follow-up period (month 113). At month 113, GMTs for both HPV-16 and HPV-18 were still at least 10-fold higher than titres observed in women previously infected but who cleared HPV infection (natural infection) and 100% of the women were seropositive for both antigens.

In study HPV-008, immunogenicity up to month 48 was similar to the response observed in study HPV-001/007. A similar kinetic profile was observed with the neutralizing antibodies.

Bridging the Efficacy of CERVARIX Demonstrated in 15 to 25 Year Old to Other Age Groups

In a pooled analysis (HPV-029, -030 & -048), 99.7% and 100% of females aged 9 years seroconverted to HPV types 16 and 18, respectively after the third dose (at month 7) with GMTs at least 1.4-fold and 2.4-fold higher as compared to females aged 10-14 years and 15 to 25 years, respectively.

In two clinical trials (HPV-012 & -013) performed in girls aged 10 to 14 years, all subjects seroconverted to both HPV type 16 and 18 after the third dose (at month 7) with GMTs at least 2-fold higher as compared to women aged 15 to 25 years.

In an ongoing clinical trial (HPV-070) performed in girls aged 9 to 14 years receiving a 2-dose schedule (0, 6 months or 0, 12 months), all subjects seroconverted to both HPV types 16 and 18 one month after the second dose. The immune response after 2 doses in females aged 9 to 14 years was demonstrated to be non-inferior to the immune response after 3 doses in women aged 15 to 25 years.

The efficacy of **CERVARIX** is inferred on the basis of immunogenicity data observed in girls vaccinated from age 9 to 14 years.

Duration of the Immune Response in Women Aged 26 Years and Older

In the Phase III study (HPV-015) in women 26 years and older all subjects seroconverted one month after the third dose. At the 84-month time point, i.e. 78 months after completion of the full vaccination course, 99.3% and 95.9% of initially seronegative women remained seropositive for anti-HPV-16 and anti-HPV-18 antibodies, respectively. Antibody titres peaked at month 7 then gradually declined up to month 18 and stabilized to reach a plateau up to month 84.

In another clinical study (HPV-014) performed in women aged 15 to 55 years (229 aged 15-25 years, 226 aged 26-45 years and 211 aged 46-55 years), all women were seropositive to both HPV type 16 and 18 after the third dose (at month 7). The GMTs were, however, lower in the 26-55 years old population compared to women aged 15 to 25 years. Subjects (142 aged 15-25 years, 172 aged 26-45 years and 156 aged 46-55 years) who completed study HPV-014 and received the 3 dose schedule were followed-up for up to 10 years in the extension study HPV-060. Ten years after administration of the first dose, 100% of subjects in the 15-25 years group, 99.2% in the 26-45 years group and 96.3% in the 46-55 years group were still seropositive for HPV-16, and 99.2%, 93.7% and 83.8% for HPV-18, respectively. In all age groups, GMTs remained 5- to 32-fold for HPV-16 and 3- to 14-fold for HPV-18 above those elicited in women who cleared a natural infection.

Comparison of Immunogenicity of CERVARIX and Gardasil

In Girls Aged 9 to 14 Years

In a comparison trial with Gardasil (study HPV-071) in girls aged 9-14 years, superiority of the immune response elicited by **CERVARIX** administered according to the 2-dose schedule 0, 6 months compared to that of Gardasil administered according to the 2-dose 0, 6 months and the standard 3-dose 0, 2, 6 months schedules was demonstrated for both HPV-16 and HPV-18 by ELISA (Table 6).

Table 6: Superiority assessment of anti-HPV-16 and anti-HPV-18 immune response for CERVARIX (2 dose schedule 0, 6 months) over Gardasil (2 dose schedule 0, 6 months and 3-dose schedule 0, 2, 6 months) one month and six months after the last dose (Total Vaccinated Cohort)

	Antibody	N	GMT	N	GMT	GMT ratio (CERVARIX / Gardasil) 95% CI (LL; UL)
Month 7		CERVARIX 0, 6 months		Gardasil 0, 6 months		
	Anti-HPV-16	357	8256	353	4886	1.7 (1.5; 1.9)
	Anti-HPV-18	357	5268	353	1166	4.5 (4.0; 5.1)
		CERVARIX 0, 6 months		Gardasil 0, 2, 6 months		
	Anti-HPV-16	357	8256	351	4789	1.7 (1.5; 1.9)
	Anti-HPV-18	357	5268	351	1636	3.2 (2.8; 3.7)
Month 12		CERVARIX 0, 6 months		Gardasil 0, 6 months		
	Anti-HPV-16	355	2217	347	1260	1.8 (1.5; 2.0)
	Anti-HPV-18	355	1296	347	261	5.0 (4.3; 5.7)
		CERVARIX 0, 6 months		Gardasil 0, 2, 6 months		
	Anti-HPV-16	355	2217	348	1567	1.4 (1.2; 1.6)
	Anti-HPV-18	355	1296	348	469	2.8 (2.4; 3.2)

GMT = geometric mean antibody titre by ELISA
N = Number of subjects with post-vaccination results available
95% CI = 95% confidence interval for the GMT ratio (Anova model - pooled variance); LL = lower limit, UL = upper limit; p-value = 0.0001
The association between antibody levels and clinical efficacy is not fully understood.

The association between antibody levels and clinical efficacy is not fully understood.

In women Aged 18 to 45 Years

In a non-inferiority comparative trial with Gardasil (study HPV-010) in women aged 18-45 years, non-inferiority of the immune response elicited by CERVARIX was demonstrated for both HPV-16 and HPV-18 neutralizing antibodies in all age cohorts up to three years after first vaccination (Table 7).

Table 7: Non-inferiority* assessment in terms of neutralizing antibody titres between CERVARIX and Gardasil for HPV-16 and HPV-18 at Month 7 and Month 60 (ATP) in study HPV-010 CERVARIX Gardasil GMT ratio CERVARIX/Gardasil

	Antibody	N	GMT	N	GMT	GMT ratio (CERVARIX / Gardasil) 95% CI (LL; UL)
Month 7		CERVARIX 0, 6 months		Gardasil 0, 6 months		
	Anti-HPV-16	357	8256	353	4886	1.7 (1.5; 1.9)
	Anti-HPV-18	357	5268	353	1166	4.5 (4.0; 5.1)
		CERVARIX 0, 6 months		Gardasil 0, 2, 6 months		
	Anti-HPV-16	357	8256	351	4789	1.7 (1.5; 1.9)
	Anti-HPV-18	357	5268	351	1636	3.2 (2.8; 3.7)
Month 12		CERVARIX 0, 6 months		Gardasil 0, 6 months		
	Anti-HPV-16	355	2217	347	1260	1.8 (1.5; 2.0)
	Anti-HPV-18	355	1296	347	261	5.0 (4.3; 5.7)
		CERVARIX 0, 6 months		Gardasil 0, 2, 6 months		
	Anti-HPV-16	355	2217	348	1567	1.4 (1.2; 1.6)
	Anti-HPV-18	355	1296	348	469	2.8 (2.4; 3.2)

GMT = geometric mean antibody titres by ELISA
N = Number of subjects with post-vaccination results available
95% CI = 95% confidence interval for the GMT ratio (Anova model - pooled variance); LL = lower limit, UL = upper limit; p-value = 0.0001
The association between antibody levels and clinical efficacy is not fully understood.

Immunogenicity in HIV Infected Women

Two clinical studies assessed safety and immunogenicity of Cervarix:

1. A study performed in 120 asymptomatic HIV infected females aged 18 to 25 years (61 subjects received Cervarix) in South Africa (HPV-020).
2. A comparative study of Cervarix and Gardasil performed in 257 asymptomatic HIV-infected females aged 15-25 years (129 subjects received Cervarix) in Brazil, Estonia, India and Thailand (HPV-019).

In both studies, seroconversion at Month 7 in HIV-infected subjects receiving Cervarix was 100% for both antigens. In HPV-019, seropositivity rate at Month 24 after Cervarix vaccination was 100% for HPV-16 antibodies and >96% for HPV-18 antibodies with a Geometric Mean Concentration (GMC) level more than 12 times higher than the response to natural HPV infection. In both studies the antibody GMCs in HIV-infected subjects appeared lower than in HIV negative subjects. The clinical relevance of this observation is unknown.

In HPV-019, superiority of immune responses (neutralizing antibodies) to both HPV-16 (GMT ratio = 2.74 [95% CI 1.83; 4.11]) and HPV-18 (GMT ratio = 7.44 [95% CI 4.79; 11.54]) antigens was demonstrated with Cervarix compared to Gardasil, at Month 7 in HIV-infected subjects.

The observed reactogenicity and safety profile of Cervarix in HIV-infected women was in line with the known safety profile in healthy subjects (see *Adverse Reactions*).

The vaccine did not affect the CD4+ cell count, the HIV viral load and the HIV clinical stage.

Immunogenicity in Males Aged 10 to 18 Years

Immunogenicity in males was assessed in 2 clinical trials HPV-011 (N=173) and HPV-040 (N=556). The data showed comparable immunogenicity in males and females. In study HPV-011, all subjects seroconverted to both HPV-16 and 18 and GMT levels were non inferior to those observed in females aged 15 to 25 years in study HPV-012.

Pharmacokinetics

Evaluation of pharmacokinetic properties is not required for vaccines.

Clinical Studies

See "Pharmacodynamics".

Pre-Clinical Safety Data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, acute and repeated dose toxicity, local tolerance, fertility, embryo-foetal and postnatal toxicity (up to the end of the lactation period).

Pharmaceutical Particulars

List of Excipients

Sodium chloride, sodium dihydrogen phosphate dihydrate, water for injections

Shelf Life

The expiry date of the vaccine is indicated on the label and packaging.

Special Precautions for Storage

Store in a refrigerator (2°C – 8°C). Do not freeze.

Store in the original package in order to protect from light.

CERVARIX should be administered as soon as possible after being removed from the refrigerator.

However, stability data generated indicate that CERVARIX presented in monodose or multidose containers remains stable and can be administered in case it has been stored outside the refrigerator for up to three days at temperatures between 8°C and 25°C or for up to one day at temperatures between 25°C and 37°C.

After first opening of the multidose vial, immediate use is recommended. If not used immediately, the vaccine should be stored in a refrigerator (2°C – 8°C). If not used within 6 hours it should be discarded.

Nature and Contents of Container

0.5 ml of suspension in a pre-filled syringe (type I glass) with a plunger stopper (rubber butyl) with or without needles.

0.5 ml of suspension in vial (type I glass) with a stopper (rubber butyl).

1 ml of suspension in vial (type I glass) with a stopper (rubber butyl) for 2 doses.

CERVARIX is presented as a turbid white suspension. Upon storage, a fine white deposit with a clear colourless supernatant can be observed.

Not all presentations are available in every country.

Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Instructions for Use/Handling

A fine white deposit with a clear colourless supernatant may be observed upon storage of the syringe/vial. This does not constitute a sign of deterioration.


The content of the syringe/vial should be inspected visually both before and after shaking for any foreign particulate matter and/or abnormal physical appearance prior to administration.

In the event of either being observed, discard the vaccine.

The vaccine should be well shaken before use.

When using a multidose vial, each 0.5 ml dose should be withdrawn using a sterile needle and syringe; precautions should be taken to avoid contamination of the contents.

Instructions for Administration of the Vaccine Presented in Pre-Filled Syringe



1. Holding the syringe barrel in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise.
2. To attach the needle to the syringe, twist the needle clockwise into the syringe until you feel it lock. (see picture)
3. Remove the needle protector, which on occasion can be a little stiff.
4. Administer the vaccine.

Any unused product or waste material should be disposed of in accordance with local requirements.

Gardasil is a trade mark owned by MSD. All other trademarks are owned by or licensed to the GSK group of companies.

Version GDSv27/IPiv21
Date of issue 14Oct2019

@[year] GSK group of companies or its licensor

Manufacturer:
GlaxoSmithKline Biologicals S.A.
89, rue de l'Institut - 1330 Rixensart
Belgium
Tel: (32) 2 656 81 11 Fax: (32) 2 656 80 00